

Clinical Study to Evaluate the Possible Efficacy and Safety of Antibodies Combination (casirivimab and imdevimab) versus standard antiviral therapy as antiviral agent against Corona virus 2 infection in hospitalized COVID-19 patients

Ahmed H. Hassan^{*}, Sahar K. Hegazy^{**}, Samar T. Radwan^{***}

^{*} Clinical pharmacy Department, Mansoura University Hospital

^{**} Clinical pharmacy Department, Faculty of Pharmacy, Tanta University

^{***} Rheumatology and Immunology Department, Faculty of medicine, Mansoura University

Abstract

Introduction:

Corona Virus induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.

Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.

Aim of Study:

1-To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19

2-To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effects

Patients and Population:

265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is included in this study and will be divided into 3 groups (1:2:2):

1- Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab))

2-group B: Remdesivir

3-group C: Favipravir

Methods:

Study design is single blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH), and prescribed by chest diseases lectures of faculty of medicine-Mansoura University. The duration of study is about 6 months after ethical approval.

Results and discussion:

Casirivimab and imdevimab achieves less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O2 therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir.

Conclusion:

From all of these results, it is concluded that Group A (Casirivimab & imdevimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.

who have an oxygen saturation (SpO_2) $\geq 94\%$ on room air at sea level.

3-Severe Illness: Individuals who have Saturation pressure of oxygen (SpO_2) $< 94\%$ on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO_2/FiO_2) < 300 mm Hg, respiratory frequency > 30 breaths/min, or lung infiltrates $> 50\%$.

4-Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunctions.

Covid-19 pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged (Umakanthan et al., 2021).

1.2. Standard and controversial antivirals used in treatment of COVID-19 (Remdesivir and Favipravir)

Regarding antiviral drugs used in treatment of COVID-19, Remdesivir is a standard antiviral against COVID-19 and has

Index Terms- Casirivimab and imdevimab, COVID-19, Favipravir, Remdesivir

I. INTRODUCTION

1.1. COVID-19 overview and classification

COVID-19 is an infectious viral disease caused by severe acute respiratory syndrome-corona virus 2 (SARS CoV-2) that has affected large number of people all over the world with high mortality rate (Okonji et al., 2021). COVID-19 infection has been classified (NIH, 2021) as:

1- Mild Illness: Individuals who have any of the various signs and symptoms of COVID-19 (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging.

2-Moderate Illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and

been approved by Food and drug administration (FDA) for treatment of mild, moderate, severe and critical hospitalized COVID-19 patients (Aleem and Kothadia, 2021). Other drugs have shown controversial antiviral activity include: favipravir, ivermectin, nitazoxanide, hydroxychloroquine, ribavirin. Favipravir became a standard antiviral which has been used for treatment of mild and moderate COVID-19 outpatients (de Almeida et al., 2020).

1.3. Advances in immunotherapy for treatment of COVID-19

Recently with the end of 2020, immunotherapy to target virus antigen has developed (Owji et al., 2020). Figure 1 shows two types of immunotherapy include active and passive immunotherapy. Active immunotherapy is to enhance body to produce antibodies against virus as by vaccination. Passive immunotherapy involves direct administration of prepared antibodies acting specifically against virus or administration of product containing antibodies like plasma (Owji et al., 2020).

There are three targets for these antibodies to work as antiviral including:

- 1) antibodies that prevent the virus attachment and entry
- 2) antibodies that inhibit the virus replication and transcription
- 3) antibodies that hinder various steps of the immune system response

Table 1 includes various types of antibodies under investigation for treatment of COVID-19 and their targets (Owji et al., 2020).

1.4. Casirivimab and Imdevimab as antibodies cocktail against COVID-19

In the present study, the point of research is antibodies cocktail including REGN3048-3051 (**casirivimab and imdevimab**). REGN3048 and REGN3051 are human monoclonal antibodies targeting the spike glycoprotein on surface of viral particles thereby preventing viral entry into human cells through the angiotensin-converting enzyme 2 (ACE2) receptor (Baum et al., 2020, Hansen et al., 2020), and have shown promising antiviral activity and need for further investigation to prove their benefit in COVID patients (Weinreich et al., 2020).

Previous study (Weinreich et al., 2020) on REGN3048-3051 has mentioned that both efficacy and safety of this antibodies cocktail are proved in COVID-19 outpatients treatment in both low (2.4 g of REGN-COV2), or high (8.0 g of REGN-COV2) dose when compared to placebo,

Efficacy is measured as

1-Virologic Efficacy

Time-weighted average change from baseline in viral load through day 7 (log₁₀ scale) in patient.

2-Clinical Efficacy

Percentage of patients with one or more medically attended visits and Symptoms offset at day 7

Safety is measured as Percentage of treated patients who experience infusion related and hypersensitivity reactions and incidence of any serious and unexpected adverse effect.

This previous study (Weinreich et al., 2020) concluded that efficacy is greater and more obvious in seronegative outpatients (whose immune response is not developed yet to produce antibodies against virus) and with high baseline viral load outpatients.

Now, data (FDA, 2021) is available for these new antibodies cocktails. The U.S. FDA has allowed an Emergency Use Authorization (EUA) for casirivimab and imdevimab combination in the treatment and post-exposure prophylaxis of mild and moderate COVID-19 in adults and pediatric outpatients (more than 12 years of age and not less than 40 kg) with positive PCR results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19 requiring hospitalization or causing death..

In contrast, REGN3048 and REGN3051 are still not authorized for use in patients (FDA, 2021):

- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
- who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity (FDA, 2021).

Now, casirivimab and imdevimab are approved investigational antibodies, Serious and unexpected adverse effects can occur that not previously reported with their use (FDA, 2021).

Confirmed adverse effects include hypersensitivity and infusion related reactions and the study have showed that there is no difference in safety profile between intravenous (I.V) infusion and subcutaneous (S.C) injection. Data about use during pregnancy and breastfeeding mother is insufficient yet. Also, Data not support any dosage adjustment in hepatic and renal patients (FDA, 2021).

This antibody combination follows linear pharmacokinetics after its single intravenous doses with half-life of about 25 to 37 days for both antibodies. Regarding elimination, this combination is not metabolized by liver cytochrome enzymes, and not excreted by kidneys (FDA, 2021).

Limitations of the previous study performed on antibody cocktail

Limitations of previous study include

- 1-short duration of follow up
- 2-not used much clinical relevant outcomes like mortality rate
- 3- Not studied the long term effect of antiviral efficacy in lowering viral load on inflammatory markers.
- 4- Study performed on non-hospitalized patients only and not included hospitalized patients (trial is done only on outpatients and not inpatients)




Fig.1: Immunization approaches against COVID-19(Owji et al., 2020)

Table 1 shows antibodies candidate against SARS-CoV-2 under investigation by pharmaceutical companies(Owji et al., 2020).

Antibody	Mechanism	Company	Stage of study/identification method
Gimsilumab	Anti GM-CSF monoclonal antibody	Roviant Sciences	In clinical stage for inflammation and rheumatic disease Prioritized in clinical trial for SARS-CoV-2
TJM2		I-MAB Biopharma	Phase 1 clinical trial completed and revealed favorable safety
Lenzilumab		Humanigen Inc.	Currently in clinical stage for leukemia and lymphoma
Canakinumab (Ilaris®)	IL-1 β inhibitor	Novartis	-In clinical stage for several inflammatory diseases including arthritis, periodic fever and lung cancer; -Repurposed by Novartis for COVID-19
Secukinumab (Cosentyx®)	IL-17 inhibitor	Novartis	In clinical stage for several autoimmune diseases including psoriasis; repurpose by Novartis for

			COVID-19
Not mentioned	Binds to highly-conserved epitopes within SARS-CoV and SARS-CoV-2	Vir biotechnology with WuXi biologics and Biogen	Enters clinical trial within 3–5 months Aimed to confer short- and long-term immunity and use as prophylaxis
Not mentioned	Block virus RBD interaction with ACE2	Distributed Bio	Computational studies; Thousands of fully human high affinity monoclonal antibodies engineered by Tumbler and SuperHuman 2.0 technology
Not mentioned	Anti SARS-CoV-2	Eli Lilly and AbCellera	Experimental stage; screened functional antibodies of recovered COVID-19 patients
TZLS-501	Fully human monoclonal antibody targeting the receptor of IL-6, it binds to both membrane-bound and soluble forms of IL-6R, and rapidly depletes the circulating levels of IL-6 in blood.	Tiziana Life Sciences and Novimmune	Preclinical stage
ALT-100	Neutralize circulating NAMPT	Aqualung Therapeutics Corp.	Preclinical stage
Not mentioned	Fully human monoclonal antibody	Harbour Biomed; Mount Sinai Health System	-Experimental stage -Produced with the technology of H2L2 Harbour mice®
Pritumumab	Fully human IgG antibody targeting vimentin	Nascent Biotech Inc.	-Received FDA approve for several carcinoma -Research began for COVID-19
Leronlimab (PRO140)	Antagonizes CCR5 on T-cells and prevents viral entry	CytoDyn	-A 10-patient clinical study against COVID-19 -Initially developed against HIV; in clinical trial for HIV and breast cancer
BDB-1	Anti C5a	Beijing Defengrei Biotechnology	Beijing Defengrei Biotechnology passes the phase II of clinical trial
IFX-1		InflaRx	InflaRx received approval for starting the clinical trial in Netherlands
Not mentioned	Fully human neutralizing antibodies targeting SARS-CoV-2	Adaptive and Amgen	Screening B cell receptors of patients recovered from COVID-19 to find neutralizing antibodies

VIR-7831/VIR-7832	-Neutralize highly conserved epitope in s protein -Induce NK-mediated antibody-dependent cell cytotoxicity	VIR biotechnology and GSK	Designed based on S309 (isolated from SARS-Cov patients)
SAB	Anti SARS-CoV-2 fully human poly clonal antibodies	SAB Biotherapeutics	-Antibodies produced in genetically engineered cattle will enter clinical trial by early summer -SAB-301 against MERS passes phase 1 of clinical trial and entered phase II/III
-	Target multiple viral S epitope	ImmunoPrecise	Using B cell Select® and Deep Display® technology
COVID-HIG and COVID-EIG	Hyperimmune polyclonal antibody derived from human plasma or immunized horse	Emergent BioSolutions	Enter clinical trial within 4–5 months
Rcig	Recombinant anti SARS-CoV-2 hyperimmune gammaglobulin, polyclonal antibodies	GigaGen	-Preclinical stage -Aimed for COVID19 hospitalized patients and prophylaxis in high risk individuals
Antibody cocktail including REGN3048-3051	Fully human multivalent antibodies against the spike protein isolated from genetically modified mice or recovered COVID-19 patients	Regeneron	-Phase 1 clinical trial for Middle East Respiratory Syndrome (MERS) completed last year -Clinical trial for SARS-CoV-2 starts by early summer

II. AIM OF THE STUDY:

1-To evaluate the efficacy of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19

2-To evaluate safety of antibodies cocktail (casirivimab and imdevimab) compared to standard antiviral therapy by monitoring of hypersensitivity and infusion related reactions or other significant adverse effects

III. PATIENTS AND POPULATION

265 COVID-19 PCR confirmed patients with indication for antiviral therapy is included in this study and will be randomized (2:1:1) into 3 groups

1- Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab))

2-group B: Remdesivir

3-group C: Favipravir

Population in this study are patients hospitalized in isolation hospital-Mansoura university.

A computer file containing a written informed consent from included patients will be provided. Paper will not be a tool for providing agreement by patients or their relatives to avoid transmission of infection.

Inclusion criteria

Patient should fulfill all this characteristics to be included:

1-age more than 12 years old.

2-weight not less than 40 kg.

3-Moderate, severe or critical COVID-19 disease as defined by WHO.

4-PCR- confirmed patients to be Positive before inclusion.

Exclusion criteria

Patient should not have any of the following to be included:

1-history of hypersensitivity or infusion related reactions after administration of monoclonal antibodies.

2-prior use of standard antiviral therapy (remdesivir or favipravir).

3-Current use of controversial antiviral therapy (hydroxychloroquine, ivermectin, nitazoxanide, oseltamivir, acyclovir, ribavirine, lopinvir/rotinvir, sofosbuvir, dectasevir, semipirvir, azithromycin).

4-patients expected to die within 48 hours.

IV. INTERVENTIONS

Population included in this study will be assigned into 3 groups with 1:2:2 ratios to receive either antibodies cocktail or standard antiviral therapy (remdesvir, favipravir) as shown in table2 and figure 2.

Group A patients will receive REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) in low-dose regimen 1.2 gm (1200 mg of combined antibodies) diluted in 250 ml 0.9% sodium chloride solution as single I.V infusion over 30-60 minutes.

Group B patients will receive Remdesivir :

Day1 (loading dose): 200 mg (two 100mg vials) diluted in 500ml 0.9% sodium chloride solution infused I.V over 60 minutes
 Day 2-5 or Day 2-10 (maintenance dose): 100 mg (one 100mg vial) in 250 ml 0.9% sodium chloride solution infused I.V over 30 minutes

Group C patients will receive Favipravir :
 Day 1 (loading dose): 1600 mg (8 tablets) or 1800 mg (9 tablets) orally or in Ryle tube / 12 hours
 Day 2-5 or day 2-10 (maintenance dose): 600 mg (3 tablets) or 800 mg (4 tablets) orally or in Ryle tube / 12 hours
 Patients will be received standard of care by Physicians, Clinical pharmacist , Nurses and as guided by Egyptian COVID-19 treatment protocol.

Table 2 : The three intervention groups of the study

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	A	53	20.0	20.0	20.0
	B	106	40.0	40.0	60.0
	C	106	40.0	40.0	100.0
	Total	265	100.0	100.0	




Figure 2: Assignment of the included COVID cases at their groups.




Figure 3: Frequency of interventions in included patients

V. METHOD

The type of this study is single blind non-RCT and is considered a Phase IV Clinical trial (post-marketing study) to report efficacy and safety of new medicine.

We use PubMed search tool to find clinical studies that performed to test efficacy and safety of developed immunotherapy in treatment of COVID-19 with about 4,000 results with focusing on antibodies developed as antiviral against COVID-19 obtaining only 70 results from which REGN-COV2, a Neutralizing Antibody Cocktail is selected with its only one clinical study up to now (REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19) which is published in New England Journal of Medicine on January 21, 2021.

Another resource used to obtain data is Fact Sheet for Health Care Providers- EUA OF casirivimab and imdevimab which provides clinical data about the use of this antibodies cocktail. Endnote citation software is used for citation of references.

VI. OUTCOMES

Parameters that will be assessed during hospitalization at day 0(baseline), day 3, 7, 14, 28 include:

- C-reactive protein (CRP)
- ferritin
- lactate dehydrogenase (LDH)
- D-dimer
- serum creatinine (S.Cr) and estimated creatinine clearance (CrCl)

- alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, bilirubin

Clinical outcomes measured before & during intervention

1) Primary outcomes

- 1- 28-days mortality rate (efficacy).
- 2-PCR test results at end of hospital visit (efficacy).
- 3-percentage of patients who developed infusion related or hypersensitivity reactions during and after the end of drug infusion and reporting of any Serious and unexpected adverse events may occur that have not been previously reported with REGEN-COV use that may cause drug discontinuation (Safety).

2) Secondary outcomes

- 1-Need for invasive mechanical ventilation (IMV)
- 2- Invasive mechanical ventilation and oxygen support duration (days).
- 3- Time to clinical improvement(Garibaldi et al., 2021) (defined as 2 points reduction in the WHO disease ordinal progression scale(Plaçais et al., 2022) or discharge, whatever happens first)
- 4- ICU and hospitalization length of stay (days).
- 5- SOFA score(Yang et al., 2021) on day 0,3,7,14, and 28.
- 6- COVID19 WHO disease progression score(Plaçais et al., 2022) from day 0 to day 28.
- 7- Inflammatory markers including CRP, ferritin, LDH
- 8- liver and kidney functions

In addition to clinical outcomes measured before and during intervention, Vital signs, glasgow coma score (GCS),complete blood count (CBC), arterial blood gas (ABG) and prothrombin time (PT) is observed daily and recorded at day0.patients' characteristics(age,gender) and relevant medical and medication history and current COVID-19 treatment drugs will be recorded on admission

Duration of research will be about 6 months from Novmber 2021 to April 2022

Sample Size

VII. Statistical analysis and Sample Size

Statistical analysis

Intention-to-treat strategy will be used in this study. Statistical analysis will be achieved with SPSS, version 26.

Categorical variables will be presented as proportion and percent. Continuous variables will be presented as mean (standard deviation) for parametric data or as a median (25th-75th percentile) for non-parametric data.

Regarding baseline characteristics, Kruskal-Wallis or ANOVA test (depending on type of data and the continous data distrubation (normal or not)) will be used to compare these characteristics between the study groups. We will report the P-value for our statistical tests with level of statistical significance will be P-value ≤ 0.05 .

In case of existiing differences in some basline characteristics, logestic regression will be performed. This allows studying the effect of these variables on the primary outcomes of the study to exclude the effect of these confounding vaiables and to ensure the effect on the outcomes is due to interventions.

Regarding the outcomes, we will compare the 28-day all-cause mortality rate, result of PCR test at hospital discharge and incidence of infusion related or hypersensitivity reactions during and after the end of drug infusion (primary outcome) using the Kruskal-Wallis test with reporting the P-value.

While the secondary outcomes (hospital stay duration, icu stay duration and others) are compared using Kruskal-Wallis or ANOVA test depending on type of data and the continous data distrubation (normal or not).

A total sample sizes of 246 patients would achieve at least 80 % power to detect a risk difference of 0.2 (20%) in the 28-day all-cause mortality (primary outcome) with a significance level (α) of 0.05 and 95% confidence level using the ANOVA or Kruskal-Wallis test of independent proportion in G*Power software. To compensate for the estimated loss-to-follow-up and increase the study power, we will increase the sample size in both remdesivir and favipravir groups to be 106 patients compared to 53 patients in Antibodies cocktail Group As Antibodies cocktail product is available for only about 50 COVID-19 patients. In addition,the ratio (1:2:2) is the closest to reality according to number of patients who recieve each drug.

The mortality data was estimated from the average mortality in Augest, Septmper, and October 2021 at the Mansoura University Isolation Hospital among all hospitalized patients. Mortality rate is found to be about 360 cases in these 3 months (120 cases / month). The online system has been used to obtain mortality rate in these three monthes.

The current admission rate at the Mansoura University – Isolation Hospital is 250 cases per month on average; our needed sample is about 250 cases.

VIII. RESULTS

After statstical analysis using SPSS software, all continous data shows no normal distrubation. So Kruskal-Wallis Test is used to compare non normally distrubated continous, catagorical and nominal variables between the three groups.

8.1. Regarding baseline characteristics

Table 3 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in baseline characteristics if they show statistically significant difference between the three groups. Figures (4-23) show distrubuations and frequencies of baseline characteristics between the three groups.

Table 3: the Significance of differences in baseline characteristics between the three groups

Variables		intervention			P-values*
		Casirivimab/Imedivimab (A)	Remdesivir (B)	Favipiravir (C)	
Age		58.34±16.096	59.30±15.985	65.02±14.261	0.006
B & C					0.07
A & C					0.07
A & B					0.63
Gender	Male	24/53	42/106	61/106	0.03
	Female	29/53	64/106	45/106	
B & C					0.09
A & C					0.145
A & B					0.501
Number of co-morbidities	0	10/53	32/106	22/106	0.022
	1	16/53	27/106	19/106	
	2	14/53	28/106	33/106	
	3	11/53	16/106	18/106	
	4	2/53	2/106	10/106	
	5	0/53	1/106	3/106	
	6	0/53	0/106	1/106	
B & C					0.06
A & C					0.320
A & B					0.207
Method of diagnosis	Symptoms only	0/53	0/106	0/106	1

s	Labs & Radiology	0/53	0/106	0/106	
	PCR confirmed	53/53	106/106	106/106	
B & C					NA
A & C					NA
A & B					NA
severity of COVID	moderate	18/53	20/106	20/106	0.024
	severe	27/53	60/106	53/106	
	critical	8/53	26/106	33/106	
B & C					0.475
A & C					0.07
A & B					0.035
WHO clinical progression score	3	0/53	1/106	0/106	0.04
	4	15/53	5/106	10/106	
	5	35/53	100/106	96/106	
	6	3/53	0/106	0/106	
B & C					0.305
A & C					0.014
A & B					0.01
Number of symptoms	2	4/53	2/106	2/106	0.01
	3	13/53	6/106	4/106	
	4	32/53	97/106	97/106	
	5	4/53	1/106	3/106	
B & C					0.482

A & C					0
A & B					0.03
Antibiotics use	Yes	53/53	106/106	106/106	1
	No	0/53	0/106	0/106	
B & C					0.102
A & C					0.002
A & B					0.075
Macrolide use	Yes	8/53	8/106	2/106	0.07
	No	45/53	98/106	104/106	
B & C					0.102
A & C					0.002
A & B					0.075
Fluroquinolones use	Yes	41/53	92/106	95/106	0.106
	No	12/53	14/106	11/106	
B & C					N/A
A & C					N/A
A & B					N/A
3rd & 4th generation cephalosporin use	Yes	39/53	86/106	83/106	0.51
	No	14/53	20/106	23/106	
B & C					N/A
A & C					N/A
A & B					N/A

Carbapenems use	Yes	.10/53	.32/106	.22/106	0.168
	No	43/53	74/106	84/106	
B & C					N/A
A & C					N/A
A & B					N/A
Piperacillin/tazobactam use	Yes	0/53	0/106	0/106	1
	No	53/53	106/106	106/106	
B & C					N/A
A & C					N/A
A & B					N/A
Amoxicillin/clavulanate use	Yes	0/53	0/106	0/106	0.472
	No	53/53	106/106	106/106	
B & C					N/A
A & C					N/A
A & B					N/A
Cotrimoxazole use	Yes	0/53	0/106	0/106	1
	No	53/53	106/106	106/106	
B & C					N/A
A & C					N/A
A & B					N/A
Linezolid use	Yes	5/53	12/106	4/106	0.115
	No	48/53	94/106	102/106	

B & C					N A
A & C					N A
A & B					N A
Teicoplanin use	Yes	1/53	0/106	2/106	0.3 65
	No	52/53	106/106	104/106	
B & C					N A
A & C					N A
A & B					N A
Anticoagulant use	Yes	49/53	101/106	96/106	0.4 11
	No	4/53	5/106	10/106	
B & C					N A
A & C					N A
A & B					N A
Dose of anticoagulant	Prophylactic	39/53	80/106	81/106	0.0 88
	Therapeutic	14/53	26/106	25/106	
B & C					N A
A & C					N A
A & B					N A
Antiplatelet use	Yes	5/53	6/106	0	0.0 12
	No	48/53	100/106	106/106	
B & C					0.0 39
A & C					0.0 05

A & B					0.2 62
Steroids use	Yes	45/53	105/106	98/106	0.0 02
	No	8/53	1/106	8/106	
B & C					0.5 0
A & C					0.0 68
A & B					0.0 01
additive-therapy use	Yes	51/53	106/106	105/106	0.1 04
	No	2/53	0/106	1/106	
B & C					N A
A & C					N A
A & B					N A
Paracetamol use	yes	50/53	105/106	106/106	0.0 19
	no	3/53	1/106	0/106	
B & C					0.5 74
A & C					0.0 06
A & B					0.0 22
Zinc use	Yes	4/53	0/106	1/106	0.0 03
	No	49/53	106/106	105/106	
B & C					0.6 14
A & C					0.0 04
A & B					0.0 01
Acetylcysteine use	Yes	52/53	106/106	106/106	0.1 35
	No	1/53	0/106	0/106	

B & C					N A
A & C					N A
A & B					N A
Lactoferrin use	Yes	1/53	0/106	0/106	0.135
	No	52/53	106/106	106/106	
B & C					N A
A & C					N A
A & B					N A
vitamin C use	Yes	4/53	7/106	1/106	0.070
	No	49/53	99/106	105/106	
B & C					N A
A & C					N A
A & B					N A
O2 therapy use	Yes	37/53	99/106	102/106	0.497
	No	16/53	7/106	4/106	
B & C					0.497
A & C					0
A & B					0
NP ⁽¹⁾ use	Yes	18/53	35/106	39/106	0.84
	No	35/53	71/106	67/106	
B & C					N A
A & C					N A
A & B					N A
SFM ⁽²⁾ use	Yes	30/53	82/106	87/106	0.0

		No	23/53	24/106	19/106	0.28
B & C						0.428
A & C						0
A & B						0.04
MR ⁽³⁾ use	Yes	8/53	33/106	14/106	0.03	
	No	45/53	73/106	92/106		
B & C					0.01	
A & C					0.783	
A & B					0.019	
HFNC ⁽⁴⁾ use	Yes	5/53	22/106	18/106	0.202	
	No	48/53	84/106	88/106		
B & C					N A	
A & C					N A	
A & B					N A	
CPAP ⁽⁵⁾ use	Yes	4/53	39/106	36/106	0.635	
	No	49/53	67/106	70/106		
B & C					0.635	
A & C					0.01	
A & B					0	
IMV ⁽⁶⁾ use	Yes	1/53	29/106	29/106	0.1	
	No	52/53	77/106	77/106		
B & C					0.1	
A & C					0	
A & B					0	
Vasopressor use	Yes	0/53	23/106	18/106	0.02	
	No	53/53	83/106	88/106		

B & C					1
A & C					0.0 16
A & B					0.0 01
Prone position	Yes	0/53	5/106	9/106	0.7
	No	53/53	101/106	97/106	5
B & C					N A
A & C					N A
A & B					N A
Heart rate		82.40±12.443	85.70±16.072	87.02±16.798	0.3 45
B & C					N A
A & C					N A
A & B					N A
Respiratory rate		24.25±3.246	25.40±5.580	24.72±5.012	0.6 52
B & C					N A
A & C					N A
A & B					N A
Body temperature		36.951±0.492	36.938±0.456	36.906±1.183	0.2 88
B & C					N A
A & C					N A
A & B					N A

O2 saturation on O2 therapy		96.26±2.391	95.86±3.795	96.01±3.130	0.9 42
B & C					N A
A & C					N A
A & B					N A
O2 saturation on RA⁽⁷⁾		92.36±4.816	87.62±7.171	88.35±7.006	0
B & C					0.4 48
A & C					0
A & B					0
AST⁽⁸⁾		45.62±38.619	52.95±35.490	54.52±67.856	0.1 08
B & C					N A
A & C					N A
A & B					N A
ALT⁽⁹⁾		33.34±27.166	33.27±22.826	42.79±77.372	0.6 0
B & C					N A
A & C					N A
A & B					N A
Bilirubin		0.5472±0.299	0.6228±0.790	0.7327±0.692	0.7 0
B & C					N A
A & C					N A
A & B					N A

Albumin	3.1774±0.461	3.1715±0.480	3.1021±0.512	0.659
B & C				N A
A & C				N A
A & B				N A
PT⁽¹⁰⁾	14.575±1.680	15.338±1.997	15.690±2.476	0.002
B & C				0.375
A & C				0
A & B				0.005
INR⁽¹¹⁾	1.2625±0.201	1.3436±0.239	1.3868±0.296	0.003
B & C				0.284
A & C				0.001
A & B				0.013
S.Cr⁽¹²⁾	1.2092±1.355	1.0999±0.924	1.8807±1.912	0
B & C				0
A & C				0
A & B				0.557
TLC⁽¹³⁾	8.6934±4.129	8.4562±5.044	11.0268±9.40	0.018
B & C				0.005
A & C				0.108
A & B				0.505
Lymphocyte	0.9658±0.521	0.9123±0.429	1.4834±5.620	0.776

B & C				N A
A & C				N A
A & B				N A
Hemoglobin	12.5958±1.58	12.4416±2.07	11.9494±2.54	0.143
B & C				N A
A & C				N A
A & B				N A
Hematocrit	39.317±6.045	36.975±5.586	35.259±8.559	0.003
B & C				0.106
A & C				0.001
A & B				0.033
Platelets	234.913±91.5	211.613±92.3	217.591±122	0.230
B & C				N A
A & C				N A
A & B				N A
LDH⁽¹⁴⁾	413.06±294.784	389.81±22.668	378.50±250.183	0.466
B & C				N A
A & C				N A
A & B				N A

CK⁽¹⁵⁾	185.96±2 07.6	228.07±3 67.1	232.75±2 87	0.1 09
B & C				N A
A & C				N A
A & B				N A
D-dimer	0.6189±0. 493	0.1433±0. 227	0.2915±0. 385	0
B & C				0.0 05
A & C				0
A & B				0
CRP⁽¹⁶⁾	61.566±3 9.71	61.292±3 5.3	95.513±1 57.8	0.1 14
B & C				N A
A & C				N A
A & B				N A
Ferritin	442.34±1 90.4	418.06±1 93.8	1158.4±6 953	0.2 30
B & C				N A
A & C				N A
A & B				N A
Sodium level	146.472± 30.7	145.243± 20	144.315± 18.5	0.2 27
B & C				N A
A & C				N A
A & B				N A

POTASSIUM	3.6228±0.	3.4701±0.	3.7903±0.	0.0
level	514	674	829	09
B & C				0.0 03
A & C				0.6 48
A & B				0.5 2
PaO₂⁽¹⁷⁾	77.868±4 1.79	56.432±3 5.30	63.294±3 9.45	0.0 05
B & C				0.2 52
A & C				0.2 0
A & B				0.0 01
PaCO₂⁽¹⁸⁾	36.689±1 2.59	37.325±1 4.60	37.603±1 2.08	0.8 91
B & C				N A
A & C				N A
A & B				N A
PaO₂/FiO₂⁽¹⁹⁾	233.5057 ±207	156.7358 ±171	164.142± 138	0.0 1
B & C				0.1 36
A & C				0.6 9
A & B				0.0 02
GCS⁽²⁰⁾	4	0	2	0
	6	0	1	0
	8	0	0	1
	9	0	0	1
	10	0	2	8

	13	0	0	3	
	14	1	4	7	
	15	52	97	86	
	4	0	2	0	
B & C					0.019
A & C					0.001
A & B					0.202
SOFA⁽²¹⁾	0	11	2	1	0
	1	1	1	4	
	2	3	9	3	
	3	12	25	17	
	4	17	36	28	
	5	7	18	17	
	6	0	6	13	
	7	2	4	9	

	8	0	3	7	
	9	0	1	3	
	10	0	1	3	
	14	0	0	1	
B & C					0.003
A & C					0
A & B					0.007

*P-value less than 0.05 is considered a statistically significant difference

(1) Nasal Prongs, (2) Simple Face Mask, (3) Mask Reservoir, (4) High Flow Nasal Cannula, (5) Continuous positive Airway Pressure, (6) Invasive Mechanical Ventilation, (7) Room Air, (8) Aspartate Aminotransferase, (9) Alanine aminotransferase, (10) Prothrombin Time, (11) International Normalized Ratio, (12) Serum Creatinine, (13) Total Leukocytic Count, (14) Lactate Dehydrogenase, (15) Creatine Kinase, (16) C-Reactive Protein, (17) Arterial Saturation pressure of Oxygen, (18) Arterial pressure of carbon dioxide, (19) a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen, (20) Glasgow Coma Score, (21) Sequential Organ Function Assessment

8.1.1. Age

There is statistically significant difference between A-C & B-C and statistically non-significant difference between A-B.




Figure 4: Frequency of Age in included patients




Figure 5: Distribution of Age across the three groups

8.1.2. Gender

There is statistically significant difference between B-C and statistically non-significant difference between A-B & A-C.

8.1.3. Number of comorbidities

There is statistically significant difference between B-C and statistically non-significant difference between A-B & A-C.




Figure 6: Frequency of co-morbidities number in included patients




Figure 7: Distribution of comorbidities number across the three groups

8.1.4. Method of diagnosis

There is statistically non-significant difference between the three groups




Figure 8: Distribution of Method of diagnosis across the three groups

8.1.5. Severity of COVID-19

There is statistically significant difference between A-B & A-C and statistically non-significant difference between C-B. There are statistically significant less severe cases in group A than groups B & C. Frequency of COVID severity in included COVID patients is presented in figure 4.




Figure 9: Frequency of COVID severity in included COVID-19 patients




Figure 10: Distribution of COVID-19 severity across the three groups

8.1.6. WHO clinical progression scale

There is statistically significant difference between A-B & A-C and statistically non-significant difference between C-B. WHO scale is statistically significant lower in group A than groups B & C.

8.1.7. Number of symptoms

There is statistically significant difference between A-B & A-C and statistically non-significant difference between C-B.




Figure 11: Frequency of number of symptoms in included patients

8.1.8. Antibiotics use

In general, there is statistically non-significant difference between the three groups in antibiotics use. There is only statistically significant difference between A-C in macrolides (azithromycin & clarithromycin) uses.

8.1.9. Anticoagulants use (enoxaparin, heparin, and rivaroxaban)

There is statistically non-significant difference between the three groups in anticoagulant use whether in prophylactic or therapeutic dose.

8.1.10. Antiplatelet use (aspirin, clopidogrel)

There is statistically significant difference between A-C and statistically non-significant difference between A-B & C-B.

8.1.11. Steroids use (dexamethasone, prednisolone and methylprednisolone)

There is statistically significant difference between A-B and statistically non-significant difference between A-C & C-B.

8.1.12. Additive therapy uses (paracetamol, vitamin C, zinc, acetyl cysteine, lactoferrin)

In general; there is statistically non-significant difference between the three groups in additive therapy use. There is only statistically significant difference between A-C in paracetamol and zinc use & A-B in zinc use.

8.1.13. Oxygen therapy use

In general, there is statistically significant difference between A-B & A-C and statistically non-significant difference between C-B. There is statistically non-significant difference between the three groups in nasal prongs and HFNC use.

There is statistically significant difference between A-B & A-C in simple face mask (SFM), Continuous Positive Airway Pressure (CPAP) or Non-Invasive Ventilation (NIV) and IMV use.

There is statistically significant difference between B-C in mask reservoir (MR) use.

8.1.14. Vasopressor use

There is statistically significant difference between A-B & A-C in vasopressor use and statistically non-significant difference between C-B. Use of vasopressors in group A is statistically significant less than groups B & C.

8.1.15. Prone positioning

There is statistically non-significant difference between the three groups.

8.1.16. Vital signs

There is statistically non-significant difference between the three groups in heart rate, respiratory rate and temperature.

8.1.17. Oxygen saturation

There is statistically non-significant difference between the three groups in O₂ saturation on O₂ therapy. But a statistically significant difference exists between A-B & A-C in O₂ saturation on Room air (RA).




Figure 12: Distribution O₂ saturation (on O₂ therapy) across the three groups




Figure 14: Distribution of PT across the three groups




Figure 13: Distribution of O₂ saturation (on RA) across the three groups

8.1.18. Liver function tests

There is statistically non-significant difference between the three groups in liver enzymes (AST & ALT), bilirubin, and albumin levels

8.1.19. Coagulation profile

There is statistically significant difference between A-B & A-C in PT and INR.




Figure 15: Distribution of INR across the three groups

8.1.20. Kidney function test

There is statistically significant difference between A-C & B-C in serum creatinine.




Figure 16: Distribution of S.Cr across the three groups.

8.1.21. Inflammatory markers

There is statistically non-significant difference between the three groups in CK, LDH, Ferritin and CRP levels

There is statistically significant difference between the three groups in D-dimer.




Figure 17: Distribution of D-dimer across the three groups.

8.1.22. Blood picture

There is statistically significant difference between B-C in TLC and A-B & A-C in hematocrit.

There is statistically non-significant difference between the three groups in lymphocytic counts, hemoglobin and platelets.




Figure 18: Distribution of TLC across the three groups




Figure 19: Distribution of hematocrit across the three groups

8.1.23. Electrolytes

There is statistically non-significant difference between the three groups in sodium level. There is statistically significant difference between B-C in Potassium level.




Figure 20: Distribution of Potassium level across the three groups

8.1.24. Blood gases

There is statistically significant difference between A-B & A-C in PaO₂ and between A-B in PaO₂/FiO₂. There is statistically non-significant difference between the three groups in PaCO₂.




Figure 21: Distribution of PaO₂ level across the three groups




Figure 22: Distribution of PaO₂/FiO₂ across the three groups

8.1.25. Consciousness level

There is statistically significant difference between A-C & B-C in GCS and statistically non-significant difference between A-B.

8.1.26. Multi-Organ Functions Assessment

There is statistically significant difference between the three groups in SOFA score.




Figure 23: Distribution of SOFA score across the three groups

8.1.27. Regression analysis

Regression analysis is performed to explore the effect of baseline characteristics (that show a statistically significant difference between the three groups) on the outcomes of the study and the possibility of existence of confounding variables.

Table 4: the best regression model for studying effects of confounding variables on 28-day mortality

	Unstandardized Coefficients		Standardized Coefficients		t	P-value
	B	Std. Error	Beta	Std. Error		
	(Constant)	.806	1.297			
age	.003	.001	.098	.053	1.835	.068
gender	.029	.044	.038	.058	.652	.515
No of co-morbidities	-.002	.015	-.007	.048	-.144	.885
Severity of COVID	-.004	.036	-.007	.059	-.123	.903
WHO clinical progression score	.024	.084	.021	.071	.288	.774
No of symptoms	.029	.033	.049	.057	.854	.394
macrolide	-.030	.083	-.027	.074	-.362	.718
fluroquinolones	.001	.068	.001	.073	.020	.984
cephalosporin	.046	.071	.052	.081	.646	.519
carbapenems	.057	.070	.065	.080	.818	.415
Amox/calv	-.191	.398	-.019	.039	-.479	.632
linezolid	-.007	.072	-.006	.058	-.097	.923
teicoplanin	-.201	.316	-.028	.044	-.636	.526
Other Antibiotics	-.029	.105	-.012	.043	-.274	.784
Anticoagulant	-.102	.099	-.069	.067	-	.303
Prophylaxis/therapeutic	-.014	.048	-.019	.063	-.298	.766
antiplatelet	-.028	.083	-.020	.060	-.340	.734
steroids	-.044	.078	-.036	.065	-.561	.576
Additive therapy	.096	.120	.041	.051	.803	.423
paracetamol	-.045	.095	-.024	.050	-.475	.635
zinc	-.101	.084	-.059	.049	-	.228
acetylcysteine	-.027	.176	-.008	.052	-.151	.880
lactoferrine	.312	.237	.092	.070	1.315	.190
Vitamin C	.044	.072	.031	.050	.615	.539
O2 therapy need	.053	.107	.038	.078	.492	.623

Nasal prongs use	-.004	.043	-.005	.055	-.083	.934
FM use	.040	.053	.046	.060	.764	.446
MR use	-.027	.050	-.029	.054	-.538	.591
HFNC use	.004	.050	.003	.048	.071	.944
CPAP	.003	.092	.004	.101	.035	.972
NIV need	.271	.103	.284	.107	2.639	.009
IMV need	.549	.091	.507	.084	6.042	.000
vasopressor	.054	.093	.042	.072	.579	.563
Prone position	-.183	.105	-.080	.046	-	.084
					1.740	
HR	.000	.001	-.008	.049	-.160	.873
RR	.006	.004	.066	.049	1.328	.186
Temp	-.042	.024	-.073	.042	-	.083
					1.744	
O2sat on O2	.002	.007	.014	.057	.250	.803
O2sat on RA	-.001	.004	-.023	.061	-.370	.712
AST	.000	.001	.046	.085	.539	.590
ALT	.000	.001	.040	.078	.506	.613
Bilirubin	.064	.036	.094	.053	1.789	.075
albumin	-.046	.042	-.056	.051	-	.272
					1.102	
PT	.001	.084	.007	.432	.017	.987
INR	-.087	.696	-.054	.431	-.125	.901
S.Cr	.030	.017	.113	.063	1.799	.074
CK	1.555E-5	.000	.012	.047	.249	.804
TLC	-.008	.005	-.116	.071	-	.105
					1.629	
Lymphocyte	.022	.009	.125	.054	2.317	.022
Hb	.021	.023	.102	.115	.889	.375
Hematocrit	-.004	.007	-.066	.118	-.557	.578
PLT	.000	.000	.047	.055	.860	.391
LDH	.000	.000	.080	.063	1.283	.201
D-dimer	.064	.047	.083	.061	1.356	.177
CRP	9.424E-5	.000	.017	.043	.403	.687
Ferritin	1.616E-6	.000	.011	.042	.270	.788
sodium	-.001	.001	-.059	.057	-	.298
					1.044	

POTASSIUM	.004	.032	.007	.053	.133	.894
PaO2	-.002	.001	-.191	.067	- 2.841	.005
PaCO2	-.005	.002	-.149	.052	- 2.852	.005
PaO2/Fio2	.001	.000	.175	.065	2.695	.008

GCS	.022	.015	.073	.048	1.505	.134
SOFA	.012	.018	.050	.077	.650	.517

8.2. Regarding outcomes of the study after intervention in the three groups

Table 5 shows the significance of difference between the three groups and also includes a pairwise comparison between every two groups in clinical outcomes if they show statistically significant difference between the three groups. Figures (24-78) show the distributions and frequencies of these outcomes across the three groups.

Table 5: the Significance of differences in baseline characteristics between the three groups

Variables	intervention			P-values*
	Casirivimab /Imedivimab (A)	Remdesivir (B)	Favipravir (C)	
AST at day 3	48.53±60.487	48.67±41.128	43.93±36.497	0.412
B & C				NA
A & C				NA
A & B				NA
AST at day 7	41.77±32.465	35.26±20.089	41.35±39.78	0.687
B & C				NA
A & C				NA
A & B				NA
AST at day 14	26.75±18.118	22.79±13.319	30.19±16.802	0.278
B & C				NA
A & C				NA
A & B				NA
AST at day 28		31±11.605	27±0	1
B & C				NA
ALT at day 3	33.62±34.535	36.46±32.585	36.16±49.86	0.298
B & C				NA
A & C				NA

A & B				NA
ALT at day 7	26±18.604	30.54±23.062	33.90±33.58	0.574
B & C				NA
A & C				NA
A & B				NA
ALT at day 14	15.75±4.856	22.42±15.788	35.38±17.55	0.017
B & C				0.01
A & C				0.041
A & B				0.616
ALT at day 28		71.75±57	39.50±13.4	1
B & C				NA
Bilirubin at day 3	0.4793±0.255	0.6457±0.654	0.7053±0.86	0.68
B & C				NA
A & C				NA
A & B				NA
Bilirubin at day 7	0.3717±0.221	0.6575±0.699	0.8886±1.54	0
B & C				0.208
A & C				0
A & B				0.001
Bilirubin at day 14	0.3625±0.110	0.494±0.2229	0.6888±0.37	0.088
B & C				NA
A & C				NA
A & B				NA
Bilirubin at day 28		0.41±0.14376	1.67±0	0.157
B & C				NA
Albumin at day 3	3.157±0.3858	2.947±0.4507	2.854±0.504	0.015
B & C				0.232
A & C				0.004

A & B				0.054
Albumin at day 7	2.98±0.40 73	2.77±0.48 37	2.644±0. 489	0.006
B & C				0.151
A & C				0.001
A & B				0.035
Albumin at day 14	3.425±0.2 872	2.82±0.41 84	2.813±0. 368	0.037
B & C				0.997
A & C				0.016
A & B				0.014
Albumin at day 28		2.575±0.3 304	2.7±0	0.48
B & C				NA
Platelets at day 3	271.64±9 7.62	253.425± 105	226.35±1 16.2	0.047
B & C				0.04
A & C				0.036
A & B				0.67
Platelets at day 7	268.829± 93.9	243.514±1 16.2	212.76±1 23.2	0.015
B & C				0.027
A & C				0.008
A & B				0.38
Platelets at day 14	248±136. 48	216.95±1 26.3	215.63±1 26.3	0.814
B & C				NA
A & C				NA
A & B				NA
Platelets at day 28		246.75±1 13	15±0	0.157
B & C				NA
S.Cr at day 3	1.0769±0. 941	0.9546±0. 865	1.6568±1 .776	0
B & C				0
A & C				0
A & B				0.971

S.Cr at day 7	0.9674±0. 752	0.9952±0. 987	1.6541±1 .9	0.001
B & C				0
A & C				0.017
A & B				0.525
S.Cr at day 14	0.775±0.2 21	0.6316±0. 152	1.45±1.7 753	0.007
B & C				0.002
A & C				0.452
A & B				0.237
S.Cr at day 28		0.525±0.1 708	1.2±0	0.157
B & C				NA
CRP at day 3	33.87±31. 44	52.61±37. 719	64.1±63. 035	0.002
B & C				0.557
A & C				0.001
A & B				0.004
CRP at day 7	14.06±14. 548	47.43±52. 631	65.73±90 .34	0
B & C				0.891
A & C				0
A & B				0
CRP at day 14	7.5±5.745	37.05±55. 395	39.31±54 .77	0.516
B & C				NA
A & C				NA
A & B				NA
CRP at day 28		39±38.41 9	96±0	0.264
B & C				NA
D-dimer at day 3	0.244±0.2 211	0.23±0.33 21	0.29±0.3 845	0.219
B & C				NA
A & C				NA
A & B				NA

D-dimer at day 7	0.109±0.1483	0.319±0.5017	0.425±0.5678	0.015
B & C				0.223
A & C				0.004
A & B				0.05
D-dimer at day 14	0.05±0.10	0.41±0.5999	0.313±0.461	0.423
B & C				NA
A & C				NA
A & B				NA
D-dimer at day 28		0.40±0.80	0.40±0	0.429
B & C				NA
CK at day 3	142.2±135.12	197.94±342.1	181.45±166	0.089
B & C				NA
A & C				NA
A & B				NA
CK at day 7	126.743±112	211.9±420.23	175.99±155	0.222
B & C				NA
A & C				NA
A & B				NA
CK at day 14	49.5±30.116	122.89±93.259	142.75±176	0.252
B & C				NA
A & C				NA
A & B				NA
CK at day 28		119.22±88.21	134.25±113	0.157
B & C				NA
LDH at day 3	351.27±258.57	404.45±214.92	354.7±204.2	0.01
B & C				0.06
A & C				0.156
A & B				0.003

LDH at day 7	271.4±165.99	371.37±196.2	349.68±201	0.007
B & C				0.382
A & C				0.017
A & B				0.002
LDH at day 14	379.75±313.9	360.89±244.8	306.88±266	0.457
B & C				NA
A & C				NA
A & B				NA
LDH at day 28		314.5±108.99	270±0	0.48
B & C				NA
Ferritin at day 3	393.04±170.2	427.25±194.8	1110±6784.6	0.106
B & C				NA
A & C				NA
A & B				NA
Ferritin at day 7	368.42±167.8	450.37±247.6	1433±8174	0.01
B & C				0.605
A & C				0.003
A & B				0.01
Ferritin at day 14	398.5±131.43	637.37±436	519.88±431	0.293
B & C				NA
A & C				NA
A & B				NA
Ferritin at day 28		1355±896.3	410±0	0.157
B & C				NA
PaO2/FiO2 at day 3	298.57±211.3	154.14±138.9	166.96±130	0
B & C				0.478
A & C				0
A & B				0

PaO2/FiO2 at day 7	320.62±9	163.55±1	178.59±1	0	
	3.64	72.6	38		
B & C				0.413	
A & C				0	
A & B				0	
PaO2/FiO2 at day 14	389.75±5	154.67±1	165.2±98	0.005	
	1.93	74	.87		
B & C				0.155	
A & C				0.022	
A & B				0.001	
PaO2/FiO2 at day 28		172.75±1	53±0	0.48	
		81			
B & C				NA	
GCS at day 3	3	0	3	6	0
	4	0	1	0	
	6	0	1	0	
	7	0	0	1	
	8	0	0	1	
	9	0	0	1	
	10	0	2	10	
	12	0	0	1	
	13	1	0	3	
	14	1	5	6	
15	51	94	77		
B & C				0.002	
A & C				0	
A & B				0.213	
GCS at day 7	3	0	10	13	0
	6	0	1	1	
	7	0	0	1	
	9	0	0	1	
	10	0	3	11	
	12	0	0	1	

	13	0	1	1	
	14	0	3	3	
	15	39	66	42	
B & C					0.003
A & C					0
A & B					0.011
GCS at day 14	3	0	6	4	0.189
	10	0	0	3	
	13	0	1	0	
	14	0	1	2	
	15	4	11	7	
B & C					NA
A & C					NA
A & B					NA
GCS at day 28	3	0	2	1	0.414
	15	0	2	0	
B & C					NA
SOFA at day 3	0	12	1	1	0
	1	3	8	6	
	2	12	12	8	
	3	18	24	16	
	4	6	40	18	
	5	0	4	16	
	6	0	5	11	
	7	1	4	12	
	8	0	4	3	
	9	0	1	7	
	10	0	0	1	
	11	0	0	3	
	12	0	2	1	
13	0	1	2		

	16	0	0	1	
B & C					0.001
A & C					0
A & B					0
SOFA at day 7	0	5	1	1	0
	1	18	4	4	
	2	12	10	10	
	3	3	13	13	
	4	0	28	7	
	5	1	7	7	
	6	0	6	5	
	7	0	2	6	
	8	0	1	4	
	9	0	2	2	
	10	0	4	2	
	11	0	3	3	
	12	0	0	3	
	13	0	1	2	
	14	0	1	2	
	15	0	1	2	
	16	0	0	1	
B & C					0.256
A & C					0
A & B					0
SOFA at day 14	0	3	1	0	0.008
	1	1	1	1	
	2	0	1	1	
	3	0	2	3	
	4	0	4	3	
	5	0	4	2	
	6	0	0	1	
	8	0	2	2	

	9	0	1	1			
	11	0	2	0			
	12	0	0	1			
	14	0	1	0			
	16	0	0	1			
B & C					0.797		
A & C					0.003		
A & B					0.004		
SOFA at day 28	0	0	1	0	0.157		
	3	0	1	0			
	12	0	1	0			
	13	0	1	0			
	17	0	0	1			
	B & C						NA
WHO scale at day 3	3	0	1	0	0		
	4	25	17	17			
	5	20	57	58			
	6	7	28	22			
	8	0	0	5			
	9	0	2	4			
	10	0	1	0			
	B & C						0.758
	A & C						0
	A & B						0
WHO scale at day 7	4	28	20	21	0		
	5	11	28	22			
	6	0	26	16			
	8	0	3	5			
	9	0	7	4			
	10	0	0	6			
B & C					0.982		
A & C					0		

A & B					0
WHO scale at day 14	4	4	2	7	0.015
	5	0	8	4	
	6	0	3	1	
	8	0	3	1	
	9	0	3	3	
B & C					0.136
A & C					0.062
A & B					0.005
WHO scale at day 28	5	0	2	0	0.136
	9	0	2	0	
	10	0	0	1	
B & C					NA
28-day mortality	Dead	1/53	34/106	43/106	0
	Alive	52/53	72/106	63/106	
B & C					0.176
A & C					0
A & B					0
Day of death		0.19±1.06 1	12.57±6.2 2	10.13±6. 530	0
B & C					0.234
A & C					0
A & B					0
Mortality at discharge	Dead	1/53	33/106	41/106	0
	Alive	52/53	73/106	65/106	
B & C					0.223
A & C					0
A & B					0
PCR at	Positive	36/53	92/106	78/106	0.011

hospital discharge	Negative	17/53	14/106	28/106	
B & C					0.021
A & C					0.42
A & B					0.007
Incidence of serious adverse effect	Yes	0/53	0/106	0/106	1
	No	53/53	106/106	106/106	
B & C					NA
A & C					NA
A & B					NA
Incidence of AKI	Yes	1/53	4/106	7/106	0.36
	No	52/53	102/106	99/106	
B & C					NA
A & C					NA
A & B					NA
Incidence of ALD	Yes	1/53	6/106	3/106	0.404
	No	52/53	100/106	103/106	
B & C					NA
A & C					NA
A & B					NA
Need for IMV	Yes	1/53	22/106	22/106	0.005
	No	52/53	84/106	84/106	
B & C					1
A & C					0.003
A & B					0.003

Duration of need for O2 therapy and IMV	3.72±3.52 7	9.2±7.107	7.46±5.0 77	0
B & C				0.119
A & C				0
A & B				0
Time to clinical improvement	7.4±3.101	8.33±6.38	7.75±4.2 65	0.933
B & C				NA
A & C				NA

A & B				NA
Duration of hospital stay	8.94±3.16 5	11.85±6.2 64	10.59±5. 26	0.011
B & C				0.054
A & C				0.185
A & B				0.004
Duration of ICU stay	1.45±1.83 5	7.6±7.614	6.69±6.2 3	0
B & C				0.51
A & C				0
A & B				0

8.2.1. effect of interventions on liver function

there is statistically non-significant difference between the three groups in liver function tests (AST, ALT, bilirubin) after using the three antivirals with no significant hepatotoxicity in each group.

there is only statistically significant difference in ALT in day 14 between B-C and in bilirubin in day 7 with albumin in day 14 between A-B & A-C while albumin in day 3,7 between A-C.

groups




Figure 24: Distribution of ALT at day 14 across the three




Figure 25: Distribution of Bilirubin at day 7 across the three groups




Figure 26: Distribution of Albumin at day 3 across the three groups




Figure 28: Distribution of Albumin at day 14 across the three groups




Figure 27: Distribution of Albumin at day 7 across the three groups

8.2.2. effect of interventions on platelet counts

there is only statistically significant difference between A-C & B-C in platelet count in day 3,7 and there are no other statistically significant differences between groups observed.




Figure 29: Distribution of platelets at day 3 across the three groups




Figure 30: Distribution of platelets at day 7 across the three groups

8.2.3. effect of interventions on kidney function

there is statistically significant difference in serum creatinine between A-C & B-C in day 3,7 and between B-C in day 14 and there are no other statistically significant differences between groups observed.




Figure 31: Distribution of S.Cr at day 3 across the three groups




Figure 32: Distribution of S.Cr at day 7 across the three groups




Figure 33: Distribution of S.Cr at day 14 across the three groups

8.2.4. effect on inflammatory markers (CRP, D-dimer, CK, LDH, Ferritin)

There is only statistically significant difference in CRP at day 3, 7, D-dimer, LDH and ferritin at day 7 between A-B & A-C, LDH in day 3 between A-B.




Figure 34: Distribution of CRP at day 3 across the three groups




Figure 35: Distribution of CRP at day 7 across the three groups




Figure 36: Distribution of D-dimer at day 7 across the three groups




Figure 37: Distribution of CK at day 7 across the three groups




Figure 38: Distribution of LDH at day 3 across the three groups




Figure 40: Frequency of CRP at day 3 across the three groups




Figure 39: Distribution of LDH at day 7 across the three groups




Figure 41: Frequency of CRP at day 7 across the three groups




Figure 42: Frequency of D-dimer at day 7 across the three groups

8.2.5. effect on consciousness level

There is statistically significant difference in GCS in day 3 between A-C & B-C and in day 7 between the three Groups and there are no other statistically significant differences between groups observed.




Figure 43: Distribution of GCS at day 3 across the three groups




Figure 44: Distribution of GCS at day 7 across the three groups

8.2.6. effect on score of multi-organ functions

There is statistically significant difference in SOFA score in day 3 between the three group and in day 7,14 between A-B & A-C and there are no other statistically significant differences between groups observed.




Figure 45: Distribution of SOFA at day 3 across the three groups




Figure 46: Frequency of SOFA score at day 3 across the three groups




Figure 48: Frequency of SOFA score at day 7 across the three groups




Figure 47: Distribution of SOFA at day 7 across the three groups




Figure 49: Distribution of SOFA at day 14 across the three groups




Figure 50: Frequency of SOFA score at day 14 across the three groups

8.2.7. effect on oxygen pressure in blood

There is statistically significant difference in PaO₂/FiO₂ in day 3,7,14 between A-B & A-C.




Figure 52: Distribution of PaO₂/FiO₂ at day 7 across the three groups




Figure 51: Distribution of PaO₂/FiO₂ at day 3 across the three groups




Figure 53: Distribution of PaO₂/FiO₂ at day 14 across the three group

8.2.8. effect on 28-day mortality (primary outcome)

There is statistically significant difference in 28-day mortality between A-B & A-C.




Figure 54: Distribution of 28-day mortality across the three groups

8.2.9. day of death in cases of mortality

There is statistically significant difference in day of death between A-B & A-C.




Figure 55: Distribution of day of death across the three groups

8.2.10. mortality at discharge

There is statistically significant difference in death at discharge between A-B & A-C.




Figure 56: Distribution of mortality at discharge across the three groups

8.2.11. PCR result at hospital discharge (primary outcome)

There is statistically significant difference in swab PCR result between A-B & B-C.




Figure 57: Distribution of PCR results at discharge across the three groups




Figure 58: Frequency of PCR results at discharge across the three groups

8.2.12. incidence of any serious adverse effect leading to drug discontinuation (primary outcome)

There is statistically non-significant difference between the three groups in causing of any serious adverse effect.




Figure 59: Distribution of serious adverse event incidence across the three groups

8.2.13. incidence of acute kidney injury (AKI) and acute liver damage (ALD)

There is statistically non-significant difference between the three groups in causing any deterioration on kidneys or liver functions.




Figure 60: Distribution of AKI incidence across the three groups




Figure 61: Frequency of AKI incidence across the three groups




Figure 62: Frequency of ALD incidence across the three groups




Figure 63: Distribution of ALD incidence across the three groups

8.2.14. need for IMV during hospitalization

There is statistically significant difference in need for IMV between A-B & A-C.




Figure 64: Distribution of IMV need across the three groups




Figure 65: Frequency of IMV need across the three groups

8.2.15. effect on number of days in which there is need for IMV or O2 therapy

There is statistically significant difference in number of days with need for IMV or oxygen therapy between A-B & A-C.




Figure 66: Distribution of O2 therapy and IMV need duration across the three groups




Figure 67: Frequency of O2 therapy and IMV need duration across the three groups

8.2.16. effect on time to clinical improvement in days

There is statistically non-significant difference between the three groups in time to clinical improvement in days




Figure 68: Distribution of Time to clinical improvement across the three groups

8.2.17. effect on hospital stay duration

There is statistically significant difference in duration of hospitalization between A-B.




Figure 69: Distribution of hospital stay duration across the three groups




Figure 70: Frequency of hospital stay duration across the three groups

8.2.18. effect on ICU stay duration

There is statistically significant difference in duration of ICU stay between A-B & A-C.




Figure 71: Distribution of ICU stay duration across the three groups




Figure 72: Frequency of ICU stay duration across the three groups

8.2.19. effect on WHO scale for COVID cases

There is statistically significant difference in WHO scale in day 3,7 between A-B & A-C and in day 14 between A-B only.




Figure 73: Distribution of WHO score at day 3 across the three groups




Figure 74: Frequency of WHO score at day 3 across the three groups




Figure 76: Frequency of WHO score at day 7 across the three groups




Figure 75: Distribution of WHO score at day 7 across the three groups




Figure 77: Distribution of WHO score at day 14 across the three groups




Figure 78: Frequency of WHO score at day 14 across the three groups

For more statistical analysis that is performed on clinical data of this study, this is a link to a SPSS output file that contains all statistical analysis of the study. an excel data sheet and a SPSS data file containing all clinical data of the cases of the three groups can be found in this link in addition to an excel data sheet for included and excluded cases with date: <https://drive.google.com/drive/folders/1X1dDQwW9vBvusutwMbeebUjN8jJqYxsh?usp=sharing>

IX. DISSCUSSION

9.1. Regarding baseline characteristics

21 Of 26 baseline characteristics show statistically significant differences between the three groups.

9.1.1. Age

The age in groups A & B is statistically significant less than that in group C.

9.1.2. Gender

There is statistically significant more female in group B group than group C.

9.1.3. Number of comorbidities

There is statistically significant more number of comorbidities in group C than Group B.

9.1.4. Severity of COVID-19

There are statistically significant less severe cases in group A than groups B & C.

9.1.5. WHO clinical progression scale

The who scale is statistically significant lower in group A than groups B & C.

9.1.6. Number of symptoms

There is statistically significant less number of symptoms in group A than groups B & C.

9.1.7. Antibiotics use

Although a statistically non-significant difference exists between the three groups in antibiotics use generally, the use of macrolide antibiotics is statistically significant more in group A group than group C.

9.1.8. Antiplatelet use

Use of antiplatelet (aspirin) is statistically significant more in group A group than group C.

9.1.9. Steroids use

Use of steroids is statistically significant more in group B than group A.

9.1.10. Additive therapy use

Use of paracetamol is statistically significant more in group C than group A and use of zinc is statistically significant more in group A than groups B & C.

9.1.11. Oxygen therapy use

In general, use of O2 therapy in group A is statistically significant less than groups B & C and O2 therapy using SFM, NIV, IMV in Group A is statistically significant less than Groups B & C, while the use of mask reservoir (MR) as O2 source is more in group B than group C.

9.1.12. Vasopressor use

Use of vasopressors in group A is statistically significant less than groups B & C.

9.1.13. Oxygen saturation

There is statistically significant more cases in group A who not need O2 therapy with statistically significant higher O2 saturation on room air than groups B & C.

9.1.14. Coagulation profile

PT and INR in group A are statistically significant less than that in groups B & C.

9.1.15. Kidney function test

Serum creatinine is statistically significant higher in group C than groups A & B.

9.1.16. Inflammatory markers

D-dimer is statistically significant higher in group A followed by group C followed by group B, $A > C > B$.

9.1.17. Blood picture

TLC is statistically significant higher in group C than group B and hematocrit is statistically significant higher in group A group than groups B & C.

9.1.18. Electrolytes

Potassium level is statistically significant higher in group C than group B.

9.1.19. Blood gases

PaO₂ and PaO₂/FiO₂ are statistically significant higher in value in group A than group B and PaO₂ is statistically significant higher in value in group A than group C.

9.1.20. Consciousness level

The consciousness level (GCS) is statistically significant lower in group C than groups A & B.

9.1.21. Multi-Organ Functions Assessment

SOFA score is higher in group C than groups A & B and in group B than group A. $A > B > C$ in multi-organ functions (better multi-organ functions in A than B and B than C)

9.2. Regression analysis

After statistical analysis of baseline characteristics of the cases of the three groups and finding that statistically significant differences in some baseline characteristics exist between the three groups. Differences exist between age, gender, number of symptoms, number of co-morbidities, severity of COVID, WHO clinical progression scale, SOFA score, use of antiplatelets, & steroid, & zinc, serum creatinine, PT, INR, TLC, D-dimer, PaO₂, PaO₂/FiO₂ and use of O₂ therapy including IMV and NIV.

So, it is necessary to exclude the effect of this variables on the outcomes of the study which represented by the primary outcome and mainly 28-day mortality. For this reason, regression analysis is performed to explore the effects of these variables on the primary outcome of the study (28-day mortality).

After regression analysis, it is found that all baseline characteristics that differ between the three groups have no effect on the study outcome with exception of need for NIV and IMV, PaO₂ and PaO₂/FiO₂ that show effect on 28-day mortality. This is explained by the need for NIV & IMV and a decline in PaO₂ and PaO₂/FiO₂ can cause an increase in 28-day mortality.

9.3. Regarding outcomes of the study after intervention in the three groups

9.3.1. effect of interventions on liver function

ALT level is statistically significant higher in group C than group B, bilirubin at day 7 is lower in group A than groups B & C. Albumin in day 14 is higher in group A than groups B & C. while albumin at day 3,7 is higher in group A than group C. From these results, it is concluded that A causes less hepatic

damage than B & C.

9.3.2. effect of interventions on platelet counts

Platelets count at day 3,7 is statistically significant lower in group C than groups A & B.

9.3.3. effect of interventions on kidney function

Serum creatinine at day 3,7 level is statistically significant higher in group C than groups A & B and at day 14 is higher in group C than group B.

9.3.4. effect on inflammatory markers (CRP, D-dimer, CK, LDH, Ferritin)

CRP at day 3,7 and D-dimer LDH & ferritin at day 7 are statistically significant lower in group A than groups B & C. LDH at day 3 is statistically significant lower in group A than group B.

From these results, it is concluded that inflammatory marker levels have been lowered by A than B & C interventions.

9.3.5. effect on consciousness level

GCS at day 3 is statistically significant lower in C than groups A & B, while GCS at day 7 is statistically significant higher in group A than groups B & C and in group B than group C ($A > B > C$).

9.3.6. effect on score of multi-organ functions

SOFA score at day 3 is statistically significant higher in group C than groups A & B and in group B than group A, SOFA score at day 7,14 is statistically significant lower in group A than groups B & C.

From these results, it is concluded that the best multi-organ functions are in this arrangement ($A > B > C$) with group A has the best multi-organ functions (lowest SOFA score).

9.3.7. effect on oxygen pressure in blood

PaO₂/FiO₂ value at day 3,7,14 is statistically significant higher in group A than groups B & C.

From these results, it is concluded that group A has more favorable oxygen level in blood than groups B & C.

9.3.8. effect on mortality at day 28 (primary outcome)

Group A has statistically significant lower 28-day mortality rate than groups B & C.

9.3.10. day of death in cases of mortality

Day of death is statistically significant less in group A than Groups B & C.

9.3.11. mortality at discharge

In addition to lower 28-day mortality, a statistically significant lower mortality rate at hospital discharge with group A than groups B & C.

9.3.12. PCR result at hospital discharge (primary outcome)

Group B has a statistically significant greater number of positive cases at discharge than groups A & C and group C has more positive cases than group A which has the highest number

of negative cases at discharge followed by group C followed by group B.

9.3.13. incidence of any serious adverse effect leading to drug discontinuation (primary outcome)

All three interventions have no any significant adverse effect that proves their safety.

9.3.14. incidence of AKI and hepatotoxicity

No any nephrotoxicity or hepatotoxicity observed with all three interventions that prove their safety.

9.3.15. need for invasive mechanical ventilation (IMV) during hospitalization

Group A has statistically significant lower need for IMV than groups B & C.

9.3.16. effect on number of days in which there is need for IMV or oxygen therapy

Group A has statistically significant less duration with need for O₂ therapy or IMV than groups B & C.

9.3.17. effect on time to clinical improvement in days

A statistically non-significant difference exists between the three groups in time to clinical improvement in days.

9.3.18. effect on hospital stay duration

Group A has statistically significant less duration of hospitalization than group B.

9.3.19. effect on ICU stay duration

Group A has statistically significant less duration of ICU stay than Groups B & C.

9.3.20. effect on WHO scale for COVID cases

Group A has statistically significant lower WHO progression scale than Groups B & C at day 3,7 and statistically significant lower WHO progression scale than Group B at day 14 that proves that less progression of the cases in Group A (lower WHO scale) than Groups B & C.

X. CONCLUSION

Casirivimab and imdevimab group achieves less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O₂ therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower WHO scale and better multi-organ functions as presented by lower SOFA score than Remdesivir and Favipravir groups.

From all of these results, it is concluded that group A (Casirivimab & imdevimab) has more favorable clinical outcomes than groups B (remdesivir) & C (favipravir).

XI. REFERENCES

ALEEM, A. & KOTHADIA, J. P. 2021. Remdesivir. *StatPearls*. Treasure Island (FL): StatPearls Publishing Copyright © .2021, StatPearls Publishing LLC

BAUM, A., FULTON, B. O., WLOGA, E., COPIN, R., PASCAL, K. E., RUSSO, V., GIORDANO, S., LANZA, K., NEGRON, N., NI, M., WEI, Y., ATWAL G. S., MURPHY, A. J., STAHL, N., YANCOPOULOS, G. D. & KYRATSOUS, C. A. 2020. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. *Science*, 369, .1014-1018

DOS ,DE ALMEIDA, S. M. V., SANTOS SOARES, J. C SANTOS, K. L., ALVES, J. E. F., RIBEIRO, A. G., JACOB Í, T. T., DA SILVA FERREIRA, C. J., DOS SANTOS, J. C., DE OLIVEIRA, J. F., DE CARVALHO JUNIOR, L. B. & DE LIMA, M. 2020. COVID-19 therapy: What weapons do we bring into .,battle? *Bioorg Med Chem* 28, 115757

FOOD AND DRUG ADMINISTRATION (FDA). 2021. *EMERGENCY USE AUTHORIZATION (EUA) OF REGEN-COVTM (casirivimab and imdevimab)* Available [Online].: <https://www.fda.gov/media/145611/download> [Accessed 13/10/2021]

GARIBALDI, B. T., WANG, K., ROBINSON, M. L., ZEGGER, S. L., BANDEEN-ROCHE, K., WANG, M. C., ALEXANDER, G. C., GUPTA, A., BOLLINGER, R. & XU, Y. 2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. *JAMA Netw .Open*, 4, e213071

HANSEN, J., BAUM, A., PASCAL, K. E., RUSSO, V., GIORDANO, S., WLOGA, E., FULTON, B. O., YAN, Y., KOON, K., PATEL, K., CHUNG, K. M., HERMANN, A., ULLMAN, E., CRUZ, J., RAFIQUE, J., LIBERTINY, C., ,A., HUANG, T., FAIRHURST MALBEC, M., LEE, W.-Y., WELSH, R., FARR, G., PENNINGTON, S., DESHPANDE, D., CHENG, J., WATTY, A., BOUFFARD, P., BABB, R., LEVENKOVA, N., CHEN, C., ZHANG, B., HERNANDEZ, A. R., SAOTOME, K., ZHOU, Y., FRANKLIN, M., SIVAPALASINGAM, S., LYE, D. C., WESTON, S., LOGUE, J., HAUPT, R., FRIEMAN, M., CHEN, G., OLSON, W., MURPHY, A. J., STAHL, N., YANCOPOULOS, G. D. & KYRATSOUS, C. A. 2020. Studies in humanized mice and convalescent

humans yield a SARS-CoV-2 antibody cocktail.
.1014-*Science*, 369, 1010

NATIONAL INSTITUTE OF HEALTH (NIH). 2021. *COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines* Available Online].: <https://www.covid19treatmentguidelines.nih.gov/> [v/

OKONJI, E. F., OKONJI, O. C., MUKUMBANG, F. C. & , VAN WYK B. 2021. Understanding varying COVID-19 mortality rates reported in Africa compared to Europe, Americas and Asia. *Trop Med Int Health*, 26, 716-719

OWJI, H., NEGAHDARIPOUR, M. & HAJIGHAHRAMANI, N. 2020. Immunotherapeutic approaches to curtail *Int. COVID-19 Immunopharmacol*, 88, 106924

PLAÇAIS, L., RICHIER, Q., NOËL, N., LACOMBE, K., MARIETTE, X. & HERMINE, O. 2022. Immune interventions in COVID-19: a matter of time? *Mucosal Immunology*, 15, 198-210

UMAKANTHAN, S., CHATTU, V. K., RANADE, A. V., DAS, D., BASAVARAJEGOWDA, A. & BUKELO, M. 2021. A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. *AIMS Public Health*, 8, 137-153

WEINREICH, D. M., SIVAPALASINGAM, S., NORTON, T., ALI, S., GAO, H., BHORE, R., MUSSER, B. J., SOO, Y., ROFAIL, D., IM, J., PERRY, C., PAN, C., HOSAIN, R., MAHMOOD, A., DAVIS, J. D., TURNER, K. C., HOOPER, A. T., HAMILTON, J. D., BAUM, A., KYRATSOUS, C. A., KIM, Y., COOK, A., KAMPMAN, W., KOHLI, A., SACHDEVA, Y., STAHL, ., GRABER, X., KOWAL, B., DICIOCCIO, T N., LIPSICH, L., BRAUNSTEIN, N., HERMAN, G. & YANCOPOULOS, G. D. 2020. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *New England Journal of Medicine*, 384, 238-.251

YANG, Z., HU, Q., HUANG, F., XIONG, S. & SUN, Y. 2021. THE PROGNOSTIC VALUE OF THE SOFA SCORE IN PATIENTS WITH COVID-19: A RETROSPECTIVE, OBSERVATIONAL STUDY. *MEDICINE (BALTIMORE)*, 100, E26900

XII. AUTHORS

First Author – **Ahmed H. Hassan**, Clinical Pharmacist, Mansoura University Hospital

Second Author – **Sahar K. Hegazy**, Professor and Head of Clinical pharmacy Department, Faculty of Pharmacy, Tanta University

Third Author – **Samar T. Radwan**, Assistant professor of Rheumatology and Immunology, Faculty of Medicine, Mansoura University

Correspondence Author – **Ahmed H. Hassan**, ahmedony26@gmail.com, 2001554658010, 2001155848245